

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM599747

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	Intellectual Property Security Agreement		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Axsome Therapeutics, Inc.		09/25/2020	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Hercules Capital, Inc., as Agent		
<b>Street Address:</b>	400 Hamilton Avenue, Suite 310		
<b>City:</b>	Palo Alto		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	94301		
<b>Entity Type:</b>	Corporation: MARYLAND		
<b>PROPERTY NUMBERS Total: 2</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	5530595	AXSOME	
<b>Registration Number:</b>	5519927	AXSOME THERAPEUTICS	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2138918763		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Email:</b>	rhonda.deleon@lw.com		
<b>Correspondent Name:</b>	Latham & Watkins LLP		
<b>Address Line 1:</b>	355 South Grand Avenue		
<b>Address Line 4:</b>	Los Angeles, CALIFORNIA 90071-1560		
<b>ATTORNEY DOCKET NUMBER:</b>	054809-0071		
<b>NAME OF SUBMITTER:</b>	Rhonda DeLeon		
<b>SIGNATURE:</b>	/Rhonda DeLeon/		
<b>DATE SIGNED:</b>	09/25/2020		
<b>Total Attachments: 113</b>			
source=Axsome - Intellectual Property Security Agreement Executed#page1.tif			
source=Axsome - Intellectual Property Security Agreement Executed#page2.tif			
source=Axsome - Intellectual Property Security Agreement Executed#page3.tif			
source=Axsome - Intellectual Property Security Agreement Executed#page4.tif			
source=Axsome - Intellectual Property Security Agreement Executed#page5.tif			

OP \$65.00 5530595





source=Axsome - Intellectual Property Security Agreement Executed#page102.tif  
source=Axsome - Intellectual Property Security Agreement Executed#page103.tif  
source=Axsome - Intellectual Property Security Agreement Executed#page104.tif  
source=Axsome - Intellectual Property Security Agreement Executed#page105.tif  
source=Axsome - Intellectual Property Security Agreement Executed#page106.tif  
source=Axsome - Intellectual Property Security Agreement Executed#page107.tif  
source=Axsome - Intellectual Property Security Agreement Executed#page108.tif  
source=Axsome - Intellectual Property Security Agreement Executed#page109.tif  
source=Axsome - Intellectual Property Security Agreement Executed#page110.tif  
source=Axsome - Intellectual Property Security Agreement Executed#page111.tif  
source=Axsome - Intellectual Property Security Agreement Executed#page112.tif  
source=Axsome - Intellectual Property Security Agreement Executed#page113.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

**THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT** (“Agreement”) dated as of September 25, 2020, is made by AXSOME THERAPEUTICS, INC., a Delaware corporation, and each domestic Subsidiary signatory hereto (individually and collectively, the “Grantor”), in favor of HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent (together with its successors and assigns in such capacity, “Agent”) for itself and the Lenders (as defined below).

### RECITALS

A. Grantor has entered into a Loan and Security Agreement with certain financial institutions party thereto (the “Lenders”) and Agent, in its capacity as administrative agent and collateral agent for itself and the Lenders, dated as of the date hereof (as amended, restated, or otherwise modified from time to time, the “Loan Agreement”). All capitalized terms used but not defined herein shall have the respective meanings given to them in the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Agent for its benefit and the benefit of the Lenders a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

### AGREEMENT

1. Grant of Security Interest. To secure its obligations under the Loan Agreement, Grantor grants and pledges to Agent for its benefit and the benefit of the Lenders a security interest in all of Grantor’s right, title and interest in, to and under its intellectual property (all of which shall collectively be called the “Intellectual Property Collateral”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “Copyrights”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions, re-examination certificates, utility models, and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “Patents”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “Trademarks”);

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “Mask Works”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing, the Intellectual Property Collateral does not include (a) any "intent to use" trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, provided, that upon submission and acceptance by the United States Patent and Trademark Office of an amendment to allege use of an intent-to-use trademark application pursuant to 15 U.S.C. Section 1060(a) (or any successor provision) such intent-to-use application shall constitute Intellectual Property Collateral, (b) non-assignable property, licenses or contracts, which by their terms require the consent of the licensor thereof or another party (but only to the extent such prohibition on transfer is enforceable under applicable law, including, without limitation, Sections 9406, 9407 and 9408 of the UCC), (c) any particular asset if the pledge thereof or the security interest therein is prohibited or restricted by applicable law, rule or regulation (including any requirement to obtain the consent of any governmental authority, regulatory authority or third party), provided that the foregoing exclusion of this clause (c) shall in no way be construed (1) to apply to the extent that any described prohibition or restriction is unenforceable under Section 9406, 9407 or 9408 of the UCC or other applicable law or (2) to apply to the extent that any consent or waiver has been obtained, or is hereafter obtained, that would permit the Agent's security interest or Lien notwithstanding the prohibition or restriction on the pledge of such asset, (d) any Excluded Accounts, including cash pledged pursuant to Permitted Liens and any Deposit Account, securities account, commodities account or other account to the extent solely and exclusively used to hold any cash pledged as a Permitted Lien, and (e) Equipment and software (and the products and proceeds thereof) subject to Permitted Liens of the type described in clause (vii) of the definition of Permitted Liens, but only to the extent and for so long as the agreements under which the equipment is financed prohibit granting a security interest therein to Lender.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Agent.

Grantor hereby authorizes Agent to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

3. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Agent with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

4. Execution in Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

5. Successors and Assigns. The provisions of this Agreement shall inure to the benefit of the parties hereto and their respective successors and assigns. Grantor shall not assign its obligations under this Agreement without Agent's express prior written consent, and any such attempted assignment shall be void and of no effect. Agent may assign, transfer, or endorse its rights hereunder pursuant to the terms of the Loan Agreement without prior notice to Grantor, and all of such rights shall inure to the benefit of Agent's successors and assigns.

6. Governing Law. This Agreement has been negotiated and delivered to Agent in the State of California, and shall have been accepted by Agent in the State of California. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.


7. Electronic Execution of Certain Other Documents. The words "execution," "execute", "signed," "signature," and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

[Signature page follows.]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

AXSOME THERAPEUTICS, INC., a Delaware corporation




By: Herriot Tabuteau, M.D.

Title: President and Chief Executive Officer



AGENT:

HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent



By: Jennifer Choe

Title: Associate General Counsel

[Signature Page to Intellectual Property Security Agreement (Hercules/Axsome)]

**TRADEMARK**  
**REEL: 007062 FRAME: 0277**

EXHIBIT A

Copyrights

None.

EXHIBIT B

Patents

Owner	Patent Application Title	Inventor(s)	Status	Application Number	Filed Date	Patent No.	Grant Date	Country
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM AND CYCLODEXTRINS	Herriot Tabuteau	Expired	62/114,215	2015-02-10			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Expired	62/259,993	2015-11-25			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Expired	PCT/US2016/026991	2016-04-11			Patent Cooperation Treaty
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	2016218992	2016-04-11	2016218992	2019-05-30	Australia
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	2976272	2016-04-11	2976272	2018-09-04	Canada
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Published	201680009582.7	2016-04-11			China
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Published	16750078.4	2016-04-11			European Patent

Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Application	253925	2016-04-11			Israel
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Allowed	2017-560488	2016-04-11			Japan
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Allowed	10-2017-7025448	2016-04-11			Korea, Republic of (KR)
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Application	PI 2017702930	2016-04-11			Malaysia
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Published	MX/a/2017/010304	2016-04-11			Mexico
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Granted	734233	2016-04-11	734233	2018-08-28	New Zealand
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Allowed	1120170612 3X	2016-04-11			Singapore
Antecip Bioventures II LLC	THERAPEUTIC COMPOSITIONS COMPRISING IMIDAZOLE AND IMIDAZOLIUM COMPOUNDS	Herriot Tabureau	Granted	14/288,241	2014-05-27	8,901,161	2014-12-02	United States of America
Antecip Bioventures II LLC	THERAPEUTIC COMPOSITIONS COMPRISING IMIDAZOLE AND IMIDAZOLIUM COMPOUNDS	Herriot Tabureau	Granted	14/288,720	2014-05-28	8,865,757	2014-10-21	United States of America

Antecip Bioventures II LLC	THERAPEUTIC COMPOSITIONS COMPRISING IMIDAZOLE AND IMIDAZOLIUM COMPOUNDS	Herriot Tabuteau	Granted	14/481,097	2014-09-09	8,962,599	2015-02-24	United States of America
Antecip Bioventures II LLC	THERAPEUTIC COMPOSITIONS COMPRISING IMIDAZOLE AND IMIDAZOLIUM COMPOUNDS	Herriot Tabuteau	Granted	14/540,333	2014-11-13	9,216,168	2015-12-22	United States of America
Antecip Bioventures II LLC	ZOLEDRONIC ACID DOSAGE FORMS FOR THE TREATMENT OF PAIN	Herriot Tabuteau	Abandoned	14/457,659	2014-08-12			United States of America
Antecip Bioventures II LLC	THERAPEUTIC COMPOSITIONS COMPRISING IMIDAZOLE AND IMIDAZOLIUM COMPOUNDS	Herriot Tabuteau	Granted	14/968,514	2015-12-14	9,408,862	2016-08-09	United States of America
Antecip Bioventures II LLC	THERAPEUTIC COMPOSITIONS COMPRISING IMIDAZOLE AND IMIDAZOLIUM COMPOUNDS	Herriot Tabuteau	All claims found invalid by the Patent Trial and Appeal Board					
Antecip Bioventures II LLC	THERAPEUTIC COMPOSITIONS COMPRISING IMIDAZOLE AND IMIDAZOLIUM COMPOUNDS	Herriot Tabuteau	Granted	15/211,827	2016-07-15	9,539,268	2017-01-10	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/348,808	2016-11-10	9,700,570	2017-07-11	United States of America
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H. Dinkla	Expired	PCT/US2015/032739	2015-05-27			Patent Cooperation Treaty

TRADEMARK

REEL: 007062 FRAME: 0281

		Graeme Jones							
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	15/459,992	2017-03-15			United States of America	
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Expired	61/900,354	2013-11-05			United States of America	
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Expired	PCT/US2014/064184	2014-11-05			Patent Cooperation Treaty	
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR REDUCING DEXTROPHAN PLASMA LEVELS AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Granted	14/550,618	2014-11-21	9,198,905	2015-12-01	United States of America	
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING ERYTHROHYDROXYBUPROPION AND RELATED COMPOUNDS FOR IMPROVING THE EFFICACY OF DEXTROMETHORPHAN	Herriot Tabuteau	Granted	14/554,988	2014-11-26	9,205,083	2015-12-08	United States of America	
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Abandoned	14/554,947	2014-11-26			United States of America	

TRADEMARK

REEL: 007062 FRAME: 0282

Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS FOR SUSTAINED DELIVERY OF DEXTROMETHORPHAN	Herriot Tabuteau	Granted	14/555,085	2014-11-26	9,238,032	2016-01-19	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS OF THEROXYBUPROPION USING THEROXYBUPROPION FOR THERAPEUTIC PURPOSES	Herriot Tabuteau	Granted	14/602,177	2015-01-21	9,402,843	2016-08-02	United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Granted	14/604,397	2015-01-23	9,168,234	2015-10-27	United States of America
Antecip Bioventures II LLC	HYDROXYBUPROPION AND RELATED COMPOUNDS AS MODULATORS OF DRUG PLASMA LEVELS	Herriot Tabuteau	Granted	14/617,624	2015-02-09	9,486,450	2016-11-08	United States of America
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION	Herriot Tabuteau	Granted	14/628,062	2015-02-20	9,402,844	2016-08-02	United States of America
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION	Herriot Tabuteau	Expired	PCT/US2015/028901	2015-05-01			Patent Cooperation Treaty
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION	Herriot Tabuteau	Abandoned	2015800741	2015-05-01			China
Antecip Bioventures II LLC	USE OF PAMIDRONATE AND RELATED COMPOUNDS FOR	Herriot Tabuteau	Expired	61/646,538	2012-05-14			United States of America

TRADEMARK

REEL: 007062 FRAME: 0283

	THE TREATMENT OF COMPLEX REGIONAL PAIN SYNDROME								
Antecip Bioventures II LLC	USE OF PAMIDRONATE, OLPADRONATE AND RELATED COMPOUNDS FOR THE TREATMENT OF PAIN	Herriot Tabuteau	Expired	61/647,478	2012-05-15			United States of America	
Antecip Bioventures II LLC	USE OF BISPHOSPHONATES FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS AND OTHER DISORDERS	Herriot Tabuteau	Expired	61/654,383	2012-06-01			United States of America	
Antecip Bioventures II LLC	USE OF INCADRONATE AND RELATED COMPOUNDS FOR THE TREATMENT OF PAIN	Herriot Tabuteau	Expired	61/654,292	2012-06-01			United States of America	
Antecip Bioventures II LLC	USE OF ZOLEDRONIC ACID AND RELATED COMPOUNDS FOR THE TREATMENT OF PAIN	Herriot Tabuteau	Expired	61/655,541	2012-06-05			United States of America	
Antecip Bioventures II LLC	ZOLEDRONIC ACID AND RELATED COMPOUNDS FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS AND OTHER DISORDERS	Herriot Tabuteau	Expired	61/655,527	2012-06-05			United States of America	
Antecip Bioventures II LLC	USE OF ZOLEDRONIC ACID AND RELATED COMPOUNDS FOR THE TREATMENT OF PAIN	Herriot Tabuteau	Expired	61/762,225	2013-02-07			United States of America	
Antecip Bioventures II LLC	USE OF ZOLEDRONIC ACID AND RELATED COMPOUNDS FOR THE TREATMENT OF PAIN	Herriot Tabuteau	Expired	61/764,563	2013-02-14			United States of America	
Antecip Bioventures II LLC	ORAL ZOLEDRONIC ACID FOR THE TREATMENT OF VARIOUS CONDITIONS	Herriot Tabuteau	Expired	61/767,676	2013-02-21			United States of America	

TRADEMARK

REEL: 007062 FRAME: 0284



Antecip Bioventures II LLC	ORAL ADMINISTRATION OF ZOLEDRONIC ACID	Herriot Tabuteau	Expired	61/767,647	2013-02-21			United States of America
Antecip Bioventures II LLC	USE OF ZOLEDRONIC ACID AND RELATED COMPOUNDS FOR THE TREATMENT OF EROSION OSTEoarthritis	Herriot Tabuteau	Expired	61/803,721	2013-03-20			United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATMENT OF COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	13/894,274	2013-05-14			United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	14/063,979	2013-10-25	8,802,658	2014-08-12	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Abandoned	14/279,241	2014-05-15			United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Expired	PCT/US2014/050427	2014-08-08			Patent Cooperation Treaty
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Abandoned	245287	2014-08-08			Israel

TRADEMARK

REEL: 007062 FRAME: 0285

Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Granted	14/863,284	2015-09-23	9,278,095	2016-03-08	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS FOR SUSTAINED DELIVERY OF DEXTROMETHORPHAN	Herriot Tabuteau	Granted	14/997,316	2016-01-15	9,457,025	2016-10-04	United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Granted	15/057,983	2016-03-01	9,408,815	2016-08-09	United States of America
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING BUPROPION	Herriot Tabuteau	Expired	62/313,067	2016-03-24			United States of America
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING BUPROPION	Herriot Tabuteau	Expired	62/313,620	2016-03-25			United States of America
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING BUPROPION	Herriot Tabuteau	Expired	62/323,438	2016-04-15			United States of America
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS	Herriot Tabuteau	Expired	62/336,533	2016-05-13			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Abandoned	15/224,233	2016-07-29			United States of America
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION	Herriot Tabuteau	Application	252417	2015-05-01			Israel

TRADEMARK

REEL: 007062 FRAME: 0286

Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	15/132,130	2016-04-18	9,821,075	2017-11-21	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING FROVATRIPAN	Herriot Tabuteau	Expired	62/504,105	2017-05-10			United States of America
Antecip Bioventures II LLC	NERIDRONIC MOLECULAR COMPLEX FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Expired	62/431,287	2016-12-07			United States of America
Antecip Bioventures II LLC	NERIDRONIC ACID FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted Claims 1-4, 9, 10, 14, 16-18, 23-25, and 27-29 found invalid and claims 5-8, 11, 13, 15, 19-22, 26, and 30 upheld by the Patent Trial and Appeal Board	15/647,140	2017-07-11	9,820,999	2017-11-21	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN	Herriot Tabuteau	Granted	14/279,229	2014-05-15	9,034,889	2015-05-19	United States of America
Antecip Bioventures II LLC	ADMINISTRATION OF ZOLEDRONIC ACID TO TREAT BACK PAIN ASSOCIATED WITH ANKYLOSING SPONDYLITIS	Herriot Tabuteau	Abandoned	14/530,556	2014-10-31			United States of America

TRADEMARK

REEL: 007062 FRAME: 0287

Antecip Bioventures II LLC	NERIDRONIC ACID FOR TREATING REGIONAL PAIN SYNDROME COMPLEX	Herriot Tabuteau	Granted All claims found invalid by the Patent Trial and Appeal Board	15/357,932	2016-11-21	9,707,245	2017-07-18	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	2014800694 91.3	2014-08-08	ZL 201480069491.3	2018-04-20	China
Antecip Bioventures II LLC	BISPHOSPHONATE COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Expired	61/933,608	2014-01-30			United States of America
Antecip Bioventures II LLC	SUBSTITUTED IMIDAZOLIUM COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	14/288,716	2014-05-28	8,835,650	2014-09-16	United States of America
Antecip Bioventures II LLC	SUBSTITUTED IMIDAZOLIUM COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	14/446,184	2014-07-29	9,006,279	2015-04-14	United States of America
Antecip Bioventures II LLC	INHIBITORS OF OSTEOCLAST ACTIVITY FOR TREATING ARTHRITIS	Herriot Tabuteau	Abandoned	14/536,526	2014-11-07			United States of America
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	Herriot Tabuteau Graeme Jones	Granted	14/604,524	2015-01-23	9,211,257	2015-12-15	United States of America

Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	Herriot Tabuteau Graeme Jones	Granted	14/605,822	2015-01-26	9,216,153	2015-12-22	United States of America
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	Herriot Tabuteau Graeme Jones	Granted	14/607,985	2015-01-28	9,289,385	2016-03-22	United States of America
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	Herriot Tabuteau Graeme Jones	Granted	15/074,367	2016-03-18	9,522,157	2016-12-20	United States of America
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	Herriot Tabuteau Graeme Jones	Granted	15/368,355	2016-12-02	9,717,747	2017-08-01	United States of America
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	Herriot Tabuteau	Granted	15/624,471	2017-06-15	9,956,237	2018-05-01	United States of America
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	Herriot Tabuteau Graeme Jones	Granted	14/967,224	2015-12-11	9,408,861	2016-08-09	United States of America
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR JOINT CONDITIONS	Herriot Tabuteau Graeme Jones	Granted	15/217,752	2016-07-22	9,610,300	2017-04-04	United States of America

Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau Graeme Jones	Granted	15/349,926	2016-11-11	9,662,343	2017-05-30	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau Graeme Jones	Granted	15/354,908	2016-11-17	9,675,626	2017-06-13	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau Graeme Jones	Granted	15/446,971	2017-03-01	9,827,192	2017-11-28	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/599,319	2017-05-18	9,855,213	2018-01-02	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING PAGET'S DISEASE OF BONE	Herriot Tabuteau	Granted	14/279,232	2014-05-15	9,149,487	2015-10-06	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING PAGET'S DISEASE OF BONE	Herriot Tabuteau	Granted	14/635,857	2015-03-02	9,283,239	2016-03-15	United States of America

	TREATING COMPLEX REGIONAL PAIN SYNDROME		Trial and Appeal Board						
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	15/055,386	2016-02-26				United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	15/347,696	2016-11-09				United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Expired	PCT/US2013/040939	2013-05-14				Patent Cooperation Treaty
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	2013262995	2013-05-14	2013262995	2016-12-15		Australia
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	2873742	2013-05-14	2873742	2018-01-16		Canada

TRADEMARK

REEL: 007062 FRAME: 0291

Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	European Patent
Antecip Bioventures II LLC	USE OF PAMIDRONATE AND RELATED COMPOUNDS FOR THE TREATMENT OF COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	2015-512753	2013-05-14			Japan
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Abandoned	10-2014-7034760	2013-05-14			Korea, Republic of (KR)
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H. Dinkla	Granted	2015267046	2015-05-27	2015267046	2018-11-01	Australia
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H. Dinkla Graeme Jones	Abandoned	2950443	2015-05-27			Canada
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H.	Abandoned	2015800337 84.0	2015-05-27			China

TRADEMARK

REEL: 007062 FRAME: 0292



		Dinkla Graeme Jones								
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H. Dinkla Graeme Jones	Abandoned	15800666.8	2015-05-27				European Patent	
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H. Dinkla Graeme Jones	Abandoned	249234	2015-05-27				Israel	
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H. Dinkla Graeme Jones	Granted	2016- 569674	2015-05-27	6457555	2018-12-28	Japan		
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H. Dinkla	Granted	10-2016- 7036115	2015-05-27	10-1975645	2019-04-29	Korea, Republic of (KR)		

		Graeme Jones							
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H. Dinkla Graeme Jones	Application	PI20167043 77	2015-05-27				Malaysia
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H. Dinkla Graeme Jones	Abandoned	MX/a/2016/ 015552	2015-05-27				Mexico
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H. Dinkla Graeme Jones	Granted	726690	2015-05-27	726690	2018-06-26		New Zealand
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H. Dinkla Graeme Jones	Granted	1120160976 7P	2015-05-27	11201609767P	2017-08-29		Singapore

Antecip Bioventures II LLC	USE OF ANTAGONISTS FOR TREATING PAIN	Herriot Tabuteau	Expired	62/010,754	2014-06-11			United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING RANK/RANKL AND RELATED COMPOUNDS FOR TREATING PAIN	Herriot Tabuteau	Expired	62/012,112	2014-06-13			United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	Herriot Tabuteau	Granted	14/495,732	2014-09-24	9,127,069	2015-09-08	United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	Herriot Tabuteau	Granted	14/812,989	2015-07-29	9,205,045	2015-12-08	United States of America
Antecip Bioventures II LLC	TREATMENT OF COMPLEX REGIONAL PAIN SYNDROME USING DENOSUMAB	Herriot Tabuteau	Granted	14/952,724	2015-11-25	9,371,392	2016-06-21	United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	Herriot Tabuteau	Granted	15/182,378	2016-06-14	9,493,571	2016-11-15	United States of America
Antecip Bioventures II LLC	METHODS USING RANK/RANKL ANTAGONIST ANTIBODIES FOR TREATING PAIN	Herriot Tabuteau	Granted	15/269,799	2016-09-19	9,688,765	2017-06-27	United States of America
Antecip Bioventures II LLC	DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	14/279,196	2014-05-15	9,301,964	2016-04-05	United States of America

TRADEMARK

Antecip Bioventures II LLC	PHARMACODYNAMIC EFFECTS AFTER ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS	Herriot Tabuteau	Expired	62/150,871	2015-04-22			United States of America
Antecip Bioventures II LLC	DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	15/043,281	2016-02-12	9,517,242	2016-12-13	United States of America
Antecip Bioventures II LLC	DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	15/136,092	2016-04-22	9,616,078	2017-04-11	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	15/188,725	2016-06-21			United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	15/164,651	2016-05-25			United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	15/353,550	2016-11-16			United States of America

TRADEMARK

REEL: 007062 FRAME: 0296

Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	Herriot Tabuteau Graeme Jones	Abandoned	15/371,052	2016-12-06			United States of America
Antecip Bioventures II LLC	NERIDRONIC MOLECULAR COMPLEX FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/384,125	2016-12-19	9,655,908	2017-05-23	United States of America
Antecip Bioventures II LLC	COMPOSITIONS ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN	Herriot Tabuteau Graeme Jones	Granted	15/385,415	2016-12-20	9,707,247	2017-07-18	United States of America
Antecip Bioventures II LLC	COMPOSITIONS ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN	Herriot Tabuteau	Granted	15/623,274	2017-06-14	9,949,993	2018-04-24	United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	702414	2013-05-14	702414	2017-01-31	New Zealand
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Abandoned	724485	2013-05-14			New Zealand

Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	733076	2013-05-14	733076	2019-01-04	New Zealand
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING ARTHRITIS	Herriot Tabuteau Graeme Jones	Abandoned	15/367,048	2016-12-01			United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	Herriot Tabuteau	Granted	14/538,709	2014-11-11	9,290,575	2016-03-22	United States of America
Asosome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Expired	62/536,466	2017-07-25			United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	Herriot Tabuteau	Abandoned	15/043,419	2016-02-12			United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATMENT OF COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	15/014,994	2016-02-03			United States of America
Antecip Bioventures II LLC	NERIDRONIC ACID FOR TREATING PAIN ASSOCIATED WITH A JOINT	Herriot Tabuteau	Granted	15/356,434	2016-11-18	9,795,622	2017-10-24	United States of America

TRADEMARK

REEL: 007062 FRAME: 0298

Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN	Herriot Tabuteau	Granted	14/686,551	2015-04-14	9,408,860	2016-08-09	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN	Herriot Tabuteau	Abandoned	15/223,548	2016-07-29			United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING DEXTROMETHORPHAN PLASMA LEVELS AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Granted	14/878,998	2015-10-08	9,314,462	2016-04-19	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Granted	15/130,807	2016-04-15	9,421,176	2016-08-23	United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Abandoned	10-2016-7032879	2013-05-14			Korea, Republic of (KR)
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Granted	15/236,290	2016-08-12	9,763,932	2017-09-19	United States of America

TRADEMARK

REEL: 007062 FRAME: 0299

Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Granted	15/691,532	2017-08-30	10,092,560	2018-10-09	United States of America
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR JOINT CONDITIONS	Herriot Tabuteau	Granted	15/716,334	2017-09-26	9,956,234	2018-05-01	United States of America
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR BONE MARROW LESIONS	Herriot Tabuteau Graeme Jones	Granted	15/217,773	2016-07-22	9,623,038	2017-04-18	United States of America
Antecip Bioventures II LLC	NERIDRONIC BONE MARROW LESION	Herriot Tabuteau	Granted	15/360,886	2016-11-23	9,770,457	2017-09-26	United States of America
Antecip Bioventures II LLC	NERIDRONIC BONE MARROW LESIONS	Herriot Tabuteau Graeme Jones	Granted	15/454,874	2017-03-09	9,844,559	2017-12-19	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING MULTIPLE MYELOMA	Herriot Tabuteau	Granted	14/279,226	2014-05-15	9,265,778	2016-02-23	United States of America
Antecip Bioventures II LLC	DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	15/042,017	2016-02-11	9,585,901	2017-03-07	United States of America

TRADEMARK

REEL: 007062 FRAME: 0300



Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	15/352,461	2016-11-15			United States of America
Antecip Bioventures II LLC	DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Abandoned	15/365,748	2016-11-30			United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN	Herriot Tabuteau	Granted	15/386,858	2016-12-21	9,925,203	2018-03-27	United States of America
Antecip Bioventures II LLC	DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	15/083,105	2016-03-28	9,616,077	2017-04-11	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Granted	15/206,057	2016-07-08	9,861,595	2018-01-09	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Granted	15/599,163	2017-05-18	9,968,568	2018-05-15	United States of America

TRADEMARK

REEL: 007062 FRAME: 0301

Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING ANKYLOSING SPONDYLITIS	Herriot Tabuteau	Granted	14/279,213	2014-05-15	9,278,106	2016-03-08	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING PAGET'S DISEASE OF BONE	Herriot Tabuteau	Granted	15/043,141	2016-02-12	9,585,902	2017-03-07	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING PAGET'S DISEASE OF BONE	Herriot Tabuteau	Granted	15/403,073	2017-01-10	10,016,446	2018-07-10	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	15/408,783	2017-01-18			United States of America
Antecip Bioventures II LLC	COMPOSITION FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	15/377,907	2016-12-13			United States of America
Antecip Bioventures II LLC	ADMINISTRATION OF ZOLEDRONIC ACID TO TREAT PAIN ASSOCIATED WITH ANKYLOSING SPONDYLITIS	Herriot Tabuteau	Abandoned	15/414,402	2017-01-24			United States of America

Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	Herriot Tabuteau	Granted	15/481,330	2017-04-06	9,884,069	2018-02-06	United States of America
Antecip Bioventures II LLC	NERIDRONIC MOLECULAR COMPLEX FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/587,246	2017-05-04	9,782,421	2017-10-10	United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Abandoned	15/213,283	2016-07-18			United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau Graeme Jones	Granted	15/439,774	2017-02-22	9,789,128	2017-10-17	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/697,267	2017-09-06	10,034,890	2018-07-31	United States of America
Antecip Bioventures II LLC	NERIDRONIC ACID FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/710,759	2017-09-20	10,080,765	2018-09-25	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING ERYTHROHYDROXYBUPROPION AND RELATED COMPOUNDS FOR IMPROVING THE EFFICACY OF DEXTROMETHORPHAN	Herriot Tabuteau	Granted	14/879,002	2015-10-08	9,375,429	2016-06-28	United States of America

TRADEMARK

REEL: 007062 FRAME: 0303

Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Granted	15/164,746	2016-05-25	9,457,023	2016-10-04	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Granted	15/263,138	2016-09-12	9,700,553	2017-07-11	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Granted	15/645,939	2017-07-10	9,867,819	2018-01-16	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS FOR SUSTAINED DELIVERY OF DEXTROMETHORPHAN	Herriot Tabuteau	Abandoned	15/238,182	2016-08-16			United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Granted	15/647,852	2017-07-12	10,080,727	2018-09-25	United States of America
Antecip Bioventures II LLC	TREATMENT OF PAIN WITH ORAL DOSAGE FORMS COMPRISING ZOLEDRONIC ACID AND AN ENHANCER	Herriot Tabuteau	Abandoned	14/456,939	2014-08-11			United States of America

Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR JOINT CONDITIONS	Herriot Tabuteau	Granted Claims 1-14 found invalid and claims 15-30 upheld by the Patent Trial and Appeal Board	15/438,513	2017-02-21	9,867,839	2018-01-16	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Granted	14/978,976	2015-12-22	9,370,513	2016-06-21	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Granted	15/182,253	2016-06-14	9,474,731	2016-10-25	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Granted	15/280,938	2016-09-29	9,707,191	2017-07-18	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Granted	15/647,069	2017-07-11	10,105,327	2018-10-23	United States of America

TRADEMARK

REEL: 007062 FRAME: 0305

Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/354,862	2016-11-17	9,895,383	2018-02-20	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	15/357,769	2016-11-21			United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/416,995	2017-01-26	9,901,589	2018-02-27	United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	Herriot Tabuteau	Granted	15/246,325	2016-08-24	9,579,323	2017-02-28	United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING DASATINIB FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	15/421,205	2017-01-31			United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN	Herriot Tabuteau	Abandoned	15/426,908	2017-02-07			United States of America

Antecip Bioventures II LLC	DOSAGE FORMS FOR ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	ORAL OR	Herriot Tabuteau	Granted	15/432,777	2017-02-14	10,111,837	2018-10-30	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	ORAL OF OR	Herriot Tabuteau	Granted	2014340649	2014-08-08	2014340649	2017-06-08	Australia
Antecip Bioventures II LLC	COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	ORAL OF OR	Herriot Tabuteau	Granted	2928350	2014-08-08	2928350	2018-01-09	Canada
Antecip Bioventures II LLC	COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	ORAL OF OR	Herriot Tabuteau	Abandoned	14856165.7	2014-08-08			European Patent
Antecip Bioventures II LLC	COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	ORAL OF OR	Herriot Tabuteau	Granted	2016-526009	2014-08-08	6166471	2017-06-30	Japan
Antecip Bioventures II LLC	COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	ORAL OF OR	Herriot Tabuteau	Granted	10-2016-7012645	2014-08-08	10-1739244	2017-05-17	Korea, Republic of (KR)
Antecip Bioventures II LLC	COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	ORAL OF OR	Herriot Tabuteau	Application	PI 2016701480	2014-08-08			Malaysia

	RELATED COMPOUNDS FOR TREATING DISEASE							
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Abandoned	MX/a/2016/005396	2014-08-08			Mexico
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Abandoned	719362	2014-08-08			New Zealand
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	1120160304 2T	2014-08-08	11201603042T	2016-11-23	Singapore
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	2017-121884	2014-08-08	6453387	2018-12-21	Japan
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	10-2017-7013050	2014-08-08	10-1975687	2019-04-29	Korea, Republic of (KR)
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Abandoned	729665	2014-08-08			New Zealand



Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	10201609548U	2014-08-08	10201609548U	2018-01-19	Singapore
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Abandoned	2017200832	2014-08-08			Australia
Antecip Bioventures II LLC	TREATMENT OF PAIN WITH ORAL DOSAGE FORMS COMPRISING ZOLEDRONIC ACID AND AN ENHANCER	Herriot Tabuteau	Expired	PCT/US2015/044190	2015-08-07			Patent Cooperation Treaty
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Granted	2014346807	2014-11-05	2014346807	2018-07-05	Australia
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Published	2929415	2014-11-05			Canada
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Published	201480072191.0	2014-11-05			China
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Published	14859589.5	2014-11-05			European Patent

TRADEMARK

REEL: 007062 FRAME: 0309

Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Application	245504	2014-11-05			Israel
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Granted	2016-552474	2014-11-05	6605485	2019-10-25	Japan
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Published	10-2016-7013970	2014-11-05			Korea, Republic of (KR)
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Application	PI2016701609	2014-11-05			Malaysia
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Allowed	MX/a/2016/005867	2014-11-05			Mexico
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Application	719892	2014-11-05			New Zealand
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Granted	11201603391X	2014-11-05	11201603391X	2019-01-03	Singapore
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Expired	61/624,694	2012-04-16			United States of America

TRADEMARK

REEL: 007062 FRAME: 0310

	RELATED COMPOUNDS AND DEXTROMETHORPHAN								
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Abandoned	13/857,017	2013-04-04			United States of America	
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Abandoned	13/943,729	2013-07-16			United States of America	
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Abandoned	14/878,980	2015-10-08			United States of America	
Antecip Bioventures II LLC	BUPROPION AND RELATED COMPOUNDS AS MODULATORS OF DRUG PLASMA LEVELS	Herriot Tabuteau	Abandoned	15/275,177	2016-09-23			United States of America	
Antecip Bioventures II LLC	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF SUFENTANIL	Herriot Tabuteau	Expired	61/484,222	2011-05-10			United States of America	
Antecip Bioventures II LLC	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF SUFENTANIL	Herriot Tabuteau	Abandoned	13/468,215	2012-05-10			United States of America	
Antecip Bioventures II LLC	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF SUFENTANIL	Herriot Tabuteau	Abandoned	15/238,614	2016-08-16			United States of America	
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Abandoned	15/216,545	2016-07-21			United States of America	

TRADEMARK

REEL: 007062 FRAME: 0311

Antecip Bioventures II LLC	COMPOSITIONS ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOWER BACK PAIN	FOR OF OR OR FOR	Herriot Tabuteau	Granted	15/378,939	2016-12-14	9,827,256	2017-11-28	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING ARTHRITIS	HERRIOT OF TABUTEAU OR GRAEME JONES	Abandoned	15/364,117	2016-11-29				United States of America
Antecip Bioventures II LLC	METHODS FOR THE SAFE ADMINISTRATION OF IMIDAZOLE OR IMIDAZOLIUM COMPOUNDS	Herriot Tabuteau	Granted	14/625,457	2015-02-18	9,427,403	2016-08-30	United States of America	
Antecip Bioventures II LLC	METHODS FOR THE SAFE ADMINISTRATION OF IMIDAZOLE OR IMIDAZOLIUM COMPOUNDS	Herriot Tabuteau	Granted	15/223,487	2016-07-29	9,694,023	2017-07-04	United States of America	
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/348,842	2016-11-10	9,669,040	2017-06-06	United States of America	
Antecip Bioventures II LLC	COMPOSITIONS ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN	Herriot Tabuteau	Abandoned	15/380,824	2016-12-15			United States of America	
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND	Herriot Tabuteau	Granted	15/164,767	2016-05-25	9,700,528	2017-07-11	United States of America	

TRADEMARK

REEL: 007062 FRAME: 0312

	RELATED PHARMACODYNAMIC EFFECTS								
Antecip Bioventures II LLC	PHARMACODYNAMIC EFFECTS AFTER ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS	Herriot Tabuteau	Expired	PCT/US201 6/028807	2016-04-22				Patent Cooperation Treaty
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	Herriot Tabuteau Graeme Jones	Granted	14/967,234	2015-12-11	9,511,081	2016-12-06	United States of America	
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS SUCH AS ZOLEDRONIC ACID FOR LOW BACK PAIN TREATMENT	Herriot Tabuteau Jaro I. Karpinen	Expired	62/127,214	2015-03-02			United States of America	
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS SUCH AS ZOLEDRONIC ACID FOR LOW BACK PAIN TREATMENT	Herriot Tabuteau Jaro I. Karpinen	Granted	14/639,013	2015-03-04	9,289,441	2016-03-22	United States of America	
Antecip Bioventures II LLC	SUBSTITUTED IMIDAZOLIUM COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau Eric K.H. Dinkla	Granted	14/608,855	2015-01-29	9,079,927	2015-07-14	United States of America	
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	Herriot Tabuteau Graeme Jones	Granted	14/607,947	2015-01-28	9,289,384	2016-03-22	United States of America	

TRADEMARK

REEL: 007062 FRAME: 0313

Antecip Bioventures II LLC	COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	ORAL OF OR	Herriot Tabuteau	Granted	14/310,811	2014-06-20	8,822,436	2014-09-02	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	ORAL OF OR	Herriot Tabuteau	Abandoned	14/336,642	2014-07-21			United States of America
Antecip Bioventures II LLC	SUBSTITUTED COMPOUNDS FOR TREATING DISEASE	IMIDAZOLIUM FOR TREATING DISEASE	Herriot Tabuteau	Granted	14/288,713	2014-05-28	8,901,162	2014-12-02	United States of America
Antecip Bioventures II LLC	TREATING DISEASE COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS	USING ORAL OF OR	Herriot Tabuteau	Abandoned	14/279,236	2014-05-15			United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING MUSCULOSKELETAL PAIN	ORAL OF OR	Herriot Tabuteau	Abandoned	14/279,206	2014-05-15			United States of America
Antecip Bioventures II LLC	TREATMENT OF USING DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS	FOR OR	Herriot Tabuteau	Abandoned	14/279,222	2014-05-15			United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID	ORAL OF OR	Herriot Tabuteau	Abandoned	14/106,291	2013-12-13			United States of America

TRADEMARK

REEL: 007062 FRAME: 0314

	RELATED COMPOUNDS FOR TREATING DISEASE							
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Abandoned	13/894,244	2013-05-14			United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING PAIN ASSOCIATED WITH ARTHRITIS	Herriot Tabuteau	Abandoned	13/894,252	2013-05-14			United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Abandoned	13/894,262	2013-05-14			United States of America
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H. Dinkla Graeme Jones	Application	1020170641 4S	2015-05-27			Singapore
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	Herriot Tabuteau Graeme Jones	Granted	15/335,381	2016-10-26	9,694,022	2017-07-04	United States of America

Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION	Herriot Tabuteau	Application	PI 2017701828	2015-05-01			Malaysia
Antecip Bioventures II LLC	PHARMACEUTICAL COMPOSITION COMPRISING BUPROPION OR RELATED COMPOSITION AND DEXTROMETHORPHAN	Herriot Tabuteau	Granted	2017-527254	2015-05-01	6602863	2019-10-18	Japan
Antecip Bioventures II LLC	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF SUFENTANIL	Herriot Tabuteau	Expired	PCT/US2012/037373	2012-05-10			Patent Cooperation Treaty
Antecip Bioventures II LLC	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF SUFENTANIL	Herriot Tabuteau	Granted	12723023.3	2012-05-10	2707032	2019-06-26	European Patent
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Expired	PCT/US2013/036836	2013-04-16			Patent Cooperation Treaty
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Abandoned	13778280.1	2013-04-16			European Patent
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Abandoned	2013249373	2013-04-16			Australia

TRADEMARK

REEL: 007062 FRAME: 0316



Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Abandoned	2870603	2013-04-16			Canada
Antecip Bioventures II LLC	ZOLEDRONIC ACID DOSAGE FORMS FOR THE TREATMENT OF PAIN	Herriot Tabuteau	Expired	PCT/US2015/044176	2015-08-07			Patent Cooperation Treaty
Antecip Bioventures II LLC	ZOLEDRONIC ACID DOSAGE FORMS FOR THE TREATMENT OF PAIN	Herriot Tabuteau	Abandoned	15831866.7	2015-08-07			European Patent
Antecip Bioventures II LLC	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF SUFENTANIL	Herriot Tabuteau	Granted	14109472.2	2012-05-10	1196252	2020-08-14	Hong Kong
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Granted	700881	2013-04-16	700881	2017-08-01	New Zealand
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Abandoned	2013800255 70.X	2013-05-14			China
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	2016256701	2013-05-14	2016256701	2018-08-23	Australia

TRADEMARK

REEL: 007062 FRAME: 0317

Antecip Bioventures II LLC	COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	Herriot Tabuteau	Abandoned	15/672,126	2017-08-08			United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	15/672,147	2017-08-08			United States of America
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION	Herriot Tabuteau	Granted	2968371	2015-05-01	2968371	2020-08-18	Canada
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	Herriot Tabuteau	Granted	15/624,428	2017-06-15	9,861,648	2018-01-09	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/587,108	2017-05-04	9,877,977	2018-01-30	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Expired	62/526,884	2017-06-29			United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Granted	15/621,882	2017-06-13	10,105,361	2018-10-23	United States of America

Antecip Bioventures II LLC	METHODS OF TREATING PAIN WITH COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS	Herriot Tabuteau	Granted	15/619,293	2017-06-09	9,920,127	2018-03-20	United States of America
Antecip Bioventures II LLC	METHODS FOR THE SAFE ADMINISTRATION OF IMIDAZOLE OR IMIDAZOLIUM COMPOUNDS	Herriot Tabuteau	Granted	15/605,730	2017-05-25	10,173,986	2019-01-08	United States of America
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	European Patent
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/604,394	2017-05-24	9,867,840	2018-01-16	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	15/498,251	2017-04-26			United States of America
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS SUCH AS ZOLEDRONIC ACID FOR LOW BACK PAIN TREATMENT	Herriot Tabuteau Jaro I. Karpainen	Granted	15/009,712	2016-01-28	9,623,036	2017-04-18	United States of America
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS SUCH AS ZOLEDRONIC ACID FOR LOW BACK PAIN TREATMENT	Herriot Tabuteau	Granted	15/484,766	2017-04-11	9,943,531	2018-04-17	United States of America

		Jaro I. Karppinen							
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTRAMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Expired	PCT/US2017/024140	2017-03-24			Patent Cooperation Treaty	
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING PAGET'S DISEASE OF BONE	Herriot Tabuteau Jaro I. Karppinen	Expired	62/445,646	2017-01-12			United States of America	
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	Herriot Tabuteau	Expired	62/405,838	2016-10-07			United States of America	
Antecip Bioventures II LLC	BISPHOSPHONATES INHIBIT PAIN, BONE LOSS AND INFLAMMATION OF COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Expired	62/378,140	2016-08-22			United States of America	
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	Herriot Tabuteau Graeme Jones	Granted	15/074,380	2016-03-18	9,623,037	2017-04-18	United States of America	
Antecip Bioventures II LLC	METHODS FOR SAFELY ADMINISTERING OF IMIDAZOLE OR IMIDAZOLIUM COMPOUNDS	Herriot Tabuteau	Expired	62/117,797	2015-02-18			United States of America	

TRADEMARK

REEL: 007062 FRAME: 0320

Antecip Bioventures II LLC	METHODS FOR THE SAFE ADMINISTRATION OF IMIDAZOLE OR IMIDAZOLIUM COMPOUNDS	Herriot Tabuteau	Expired	62/116,609	2015-02-16		United States of America
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	2015350559	2015-05-01	2015350559	Australia
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	10-2017-7017050	2015-05-01	10-1931896	Korea, Republic of (KR)
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Application	MX/a/2017/006653	2015-05-01		Mexico
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Application	732140	2015-05-01		New Zealand
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	11201704066V	2015-05-01	11201704066V	Singapore
Antecip Bioventures II LLC	DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Expired	62/053,619	2014-09-22		United States of America

TRADEMARK

REEL: 007062 FRAME: 0321

Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	17102727.7	2014-08-08	HK1228800	2019-06-28	Hong Kong
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Published	17102591.0	2014-11-05			Hong Kong
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Abandoned	MX/a/2016/009026	2014-08-08			Mexico
Antecip Bioventures II LLC	ZOLEDRONIC ACID DOSAGE FORMS FOR THE TREATMENT OF PAIN	Herriot Tabuteau	Abandoned	14/329,844	2014-07-11			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Abandoned	62/536,465	2017-07-25			United States of America
Antecip Bioventures II LLC	PHARMACEUTICAL COMPOSITIONS COMPRISING NALBUPHINE AND NAPROXEN	Herriot Tabuteau	Expired	61/616,638	2012-03-28			United States of America
Antecip Bioventures II LLC	PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND MOXONIDINE	Herriot Tabuteau	Expired	61/611,189	2012-03-15			United States of America
Antecip Bioventures II LLC	PHARMACEUTICAL COMPOSITIONS COMPRISING TILIDINE AND DEXTROMETHORPHAN	Herriot Tabuteau	Expired	61/489,582	2011-05-24			United States of America

TRADEMARK

REEL: 007062 FRAME: 0322

Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING TILDINE OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Granted	13/478,023	2012-05-22	8,569,328	2013-10-29	United States of America
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H. Dinkla Graeme Jones	Granted	2017213506	2015-05-27	2017213506	2017-12-21	Australia
Antecip Bioventures II LLC	PHARMACEUTICAL COMPOSITIONS COMPRISING NALBUPHINE AND CELECOXIB OR RELATED COMPOUNDS	Herriot Tabuteau	Expired	61/635,319	2012-04-19			United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Abandoned	254123	2014-08-08			Israel
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING FROYATRRIPTAN	Herriot Tabuteau	Expired	62/442,136	2017-01-04			United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING ANKYLOSING SPONDYLITIS	Herriot Tabuteau	Abandoned	15/697,211	2017-09-06			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Granted	15/691,549	2017-08-30	10,064,857	2018-09-04	United States of America

Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS FOR SUSTAINED DELIVERY OF DEXTROMETHORPHAN	Herriot Tabuteau	Granted	15/695,995	2017-09-05	10,092,561	2018-10-09	United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Granted	15/688,660	2017-08-28	10,058,518	2018-08-28	United States of America
Antecip Bioventures II LLC	NERIDRONIC ACID FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/703,891	2017-09-13	9,931,352	2018-04-03	United States of America
			All claims found invalid by the Patent Trial and Appeal Board					
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/702,616	2017-09-12	10,004,756	2018-06-26	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING ARTHRITIS	Herriot Tabuteau Graeme Jones	Abandoned	15/707,238	2017-09-18			United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	15/707,673	2017-09-18			United States of America

TRADEMARK

REEL: 007062 FRAME: 0324



Antecip Bioventures II LLC	THERAPEUTIC COMPOSITIONS COMPRISING IMIDAZOLE AND IMIDAZOLIUM COMPOUNDS	Herriot Tabuteau Eric K.H. Dinkla	Abandoned	17110012.4	2017-10-03			Hong Kong
Antecip Bioventures II LLC	NERIDRONIC ACID COMPLEX FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/804,781	2017-11-06	9,999,628	2018-06-19	United States of America
Antecip Bioventures II LLC	NERIDRONIC ACID FOR TREATING ARTHRITIS	Herriot Tabuteau	Granted	15/840,066	2017-12-13	10,039,773	2018-08-07	United States of America
Antecip Bioventures II LLC	NERIDRONIC ACID COMPLEX FOR REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/782,480	2017-10-12	10,039,774	2018-08-07	United States of America
			All claims found invalid by the Patent Trial and Appeal Board					
Antecip Bioventures II LLC	BUPROPION AND DEXTROMETHORPHAN FOR TREATING NICOTINE ADDICTION	Herriot Tabuteau	Expired	62/576,538	2017-10-24			United States of America
Antecip Bioventures II LLC	COMPOSITIONS OF ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN	Herriot Tabuteau	Granted	15/787,612	2017-10-18	9,956,238	2018-05-01	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	15/797,955	2017-10-30	10,058,614	2018-08-28	United States of America

Antecip Bioventures II LLC	COMPOSITIONS COMPRISING NERIDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Abandoned	736712	2013-05-14			New Zealand
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/806,236	2017-11-07	10,028,908	2018-07-24	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/801,049	2017-11-01	9,999,629	2018-06-19	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	15/801,028	2017-11-01			United States of America
Antecip Bioventures II LLC	DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	15/934,785	2018-03-23	10,111,894	2018-10-30	United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Abandoned	2987470	2013-05-14			Canada

Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/808,794	2017-11-09	10,016,445	2018-07-10	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/814,745	2017-11-16	10,028,969	2018-07-24	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	15/842,599	2017-12-14			United States of America
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS SUCH AS ZOLEDRONIC ACID FOR LOW BACK PAIN TREATMENT	Herriot Tabuteau	Granted	15/879,107	2018-01-24	10,092,581	2018-10-09	United States of America
Antecip Bioventures II LLC	NERIDRONIC ACID FOR TREATING REGIONAL PAIN SYNDROME	Jaro I. Kauppinen	Granted	15/820,305	2017-11-21	10,052,338	2018-08-21	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND	Herriot Tabuteau	Granted	15/821,563	2017-11-22	10,512,643	2019-12-24	United States of America
		All claims found invalid by the Patent Trial and Appeal Board						

TRADEMARK

REEL: 007062 FRAME: 0327

	RELATED PHARMACODYNAMIC EFFECTS								
Antecip Bioventures II LLC	ZOLEDRONIC ACID DOSAGE FORMS FOR THE TREATMENT OF PAIN	Herriot Tabuteau	Published	17112071.8	2015-08-07				Hong Kong
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Published	15/856,853	2017-12-28				United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Published	17206293.7	2013-05-14				European Patent
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H. Dinkla Graeme Jones	Granted	2017272199	2015-05-27	2017272199	2019-07-11		Australia
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	15/850,503	2017-12-21				United States of America
Assome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Expired	PCT/US2018/012433	2018-01-04				Patent Cooperation Treaty

TRADEMARK

REEL: 007062 FRAME: 0328

Antecip Bioventures II LLC	BISPHOSPHONATES INCREASING THE CHARACTER OF A MODIC CHANGE	FOR TYPE 2	Herriot Tabuteau Jaro I. Karpinen	Abandoned	15/977,413	2018-05-11			United States of America
Antecip Bioventures II LLC	BISPHOSPHONATES INCREASING THE CHARACTER OF A MODIC CHANGE	FOR TYPE 2	Herriot Tabuteau Jaro I. Karpinen	Expired	PCT/US2018/013625	2018-01-12			Patent Cooperation Treaty
Antecip Bioventures II LLC	TREATMENT OF PAIN WITH ORAL DOSAGE FORMS COMPRISING ZOLEDRONIC ACID AND AN ENHANCER		Herriot Tabuteau	Abandoned	15/887,271	2018-02-02			United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN		Herriot Tabuteau	Abandoned	2018200023	2013-04-16			Australia
Antecip Bioventures II LLC	COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	ORAL OF OR	Herriot Tabuteau	Abandoned	1020180000 IV	2014-08-08			Singapore
Antecip Bioventures II LLC	COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING ARTHRITIS	ORAL OF OR	Herriot Tabuteau	Abandoned	15/877,067	2018-01-22			United States of America
Assome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION		Herriot Tabuteau	Expired	62/634,718	2018-02-23			United States of America

TRADEMARK

REEL: 007062 FRAME: 0329

Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Granted	15/933,075	2018-03-22	10,251,879	2019-04-09	United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	Herriot Tabuteau	Abandoned	15/910,945	2018-03-02			United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN	Herriot Tabuteau	Granted	15/897,947	2018-02-15	10,463,682	2019-11-05	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Abandoned	2018101501 56,6	2014-08-08			China
Antecip Bioventures II LLC	COMBINATION OF ORAL BISPHOSPHONATES WITH ACID INHIBITORS	Herriot Tabuteau	Expired	62/626,269	2018-02-05			United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	15/952,017	2018-04-12	10,335,424	2019-07-02	United States of America
Antecip Bioventures II LLC	USE OF ZOLEDRONIC ACID AND RELATED COMPOUNDS FOR THE TREATMENT OF ARTHRITIS	Herriot Tabuteau	Abandoned	2018-075822	2013-05-14			Japan
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR	Herriot Tabuteau	Granted	15/954,457	2018-04-16	10,265,332	2019-04-23	United States of America

	RELATED COMPOUNDS FOR TREATING DISEASE								
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H. Dinkla Graeme Jones	Application	739880	2015-05-27				New Zealand
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	15/902,770	2018-02-22	10,029,010	2018-07-24		United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04		Albania
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04		Austria
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04		Belgium

Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Cyprus (Republic of)
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Czechia
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Denmark
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Finland

TRADEMARK

REEL: 007062 FRAME: 0332



	PAIN AND RELATED CONDITIONS								
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	France	
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Germany (Federal Republic of)	
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Greece	
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Hungary	
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Iceland	

TRADEMARK

REEL: 007062 FRAME: 0333

Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Ireland (Republic of)
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Italy
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Latvia
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Lithuania
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Luxembourg
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	North Macedonia

	PAIN AND RELATED CONDITIONS								
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Malta	
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Monaco	
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Netherlands	
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Norway	
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Poland	

TRADEMARK

REEL: 007062 FRAME: 0335

Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Portugal
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Romania
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	San Marino
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Serbia
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Slovak Republic
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Slovenia

	PAIN AND RELATED CONDITIONS								
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Spain	
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Sweden	
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Switzerland	
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	Turkey	
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	13791356.2	2013-05-14	2849758	2018-04-04	United Kingdom	

TRADEMARK

REEL: 007062 FRAME: 0337

Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	15/936,176	2018-03-26	10,137,131	2018-11-27	United States of America
Antecip Bioventures II LLC	USE OF PAMIDRONATE AND RELATED COMPOUNDS FOR THE TREATMENT OF COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	J/003106(977)	2014-08-08	J/003106	2018-08-16	Macau
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM AND CYCLODEXTRINS	Herriot Tabuteau	Published	18103289.4	2016-04-11			Hong Kong
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Expired	62/634,726	2018-02-23			United States of America
Axsome Therapeutics, Inc.	DOSAGE FORM AND METHODS FOR ENANTIONOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Expired	62/634,731	2018-02-23			United States of America
Antecip Bioventures II LLC	METHODS FOR MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION	Herriot Tabuteau	Published	18102743.6	2015-05-01			Hong Kong
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Expired	62/639,450	2018-03-06			United States of America
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Expired	62/639,454	2018-03-06			United States of America

TRADEMARK

REEL: 007062 FRAME: 0338

Antecip Bioventures II LLC	BUPROPION AND DEXTROMETHORPHAN FOR TREATING NICOTINE ADDICTION	Herriot Tabuteau	Expired	62/645,751	2018-03-20			United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	15/962,854	2018-04-25	10,111,891	2018-10-30	United States of America
Antecip Bioventures II LLC	DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	15/982,794	2018-05-17	10,137,139	2018-11-27	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Granted	15/977,276	2018-05-11	10,463,634	2019-11-05	United States of America
Antecip Bioventures II LLC	DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	15/989,641	2018-05-25	10,420,782	2019-09-24	United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Granted	2018214132	2013-05-14	2018214132	2019-10-24	Australia

TRADEMARK

REEL: 007062 FRAME: 0339

Antecip Bioventures II LLC	DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	15/997,470	2018-06-04	10,238,672	2019-03-26	United States of America
Antecip Bioventures II LLC	NERIDRONIC ACID FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	15/963,878	2018-04-26	10,117,880	2018-11-06	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Application	742220	2016-04-11			New Zealand
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	15/984,055	2018-05-18	10,265,399	2019-04-23	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/000,701	2018-06-05	10,307,484	2019-06-04	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	15/988,104	2018-05-24	10,265,400	2019-04-23	United States of America
Antecip Bioventures II LLC	DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	16/002,888	2018-06-07	10,195,223	2019-02-05	United States of America
Antecip Bioventures II LLC	DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	15/997,530	2018-06-04	10,195,141	2019-02-05	United States of America

TRADEMARK



Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Granted	16/006,548	2018-06-12	10,463,736	2019-11-05	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Granted	16/006,642	2018-06-12	10,369,224	2019-08-06	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Expired	PCT/US2018/032162	2018-05-10			Patent Cooperation Treaty
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Granted	15/976,800	2018-05-10	10,471,068	2019-11-12	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Granted	15/989,734	2018-05-25	10,195,279	2019-02-05	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Granted	15/986,215	2018-05-22	10,195,278	2019-02-05	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Granted	16/006,692	2018-06-12	10,369,225	2019-08-06	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Granted	16/001,697	2018-06-06	10,471,014	2019-11-12	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabureau	Granted	2018203638	2014-11-05	2018203638	2019-10-31	Australia

TRADEMARK

REEL: 007062 FRAME: 0341

Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/002,865	2018-06-07	10,583,088	2020-03-10	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Expired	62/680,956	2018-06-05			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Allowed	16/107,472	2018-08-21			United States of America
Axsome Therapeutics, Inc.	METHODS OF MODULATING TETRABENAZINE METABOLITES PLASMA LEVELS USING BUPROPION	Herriot Tabuteau	Expired	62/682,998	2018-06-10			United States of America
Axsome Therapeutics, Inc.	METHODS OF MODULATING TETRABENAZINE METABOLITES PLASMA LEVELS USING BUPROPION	Herriot Tabuteau	Expired	62/683,399	2018-06-11			United States of America
Axsome Therapeutics, Inc.	COMPOSITIONS FOR DELIVERY OF REBOXETINE	Herriot Tabuteau	Expired	62/686,075	2018-06-17			United States of America
Axsome Therapeutics, Inc.	COMPOSITIONS FOR DELIVERY OF REBOXETINE	Herriot Tabuteau	Expired	62/688,333	2018-06-21			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Expired	62/693,871	2018-07-03			United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND	Herriot Tabuteau	Granted	16/119,852	2018-08-31	10,780,066	2020-09-22	United States of America

TRADEMARK

REEL: 007062 FRAME: 0342

	RELATED PHARMACODYNAMIC EFFECTS								
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Expired	62/794,469	2019-01-18			United States of America	
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Application	3011562	2016-04-11			Canada	
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	2018-567235	2018-05-10	6609071	2019-11-01	Japan	
Anecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Published	18114512.0	2013-05-14			Hong Kong	
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Expired	62/734,021	2018-09-20			United States of America	
Anecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Published	16/114,886	2018-08-28			United States of America	
Anecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Published	16/129,531	2018-09-12			United States of America	

Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Granted	16/127,832	2018-09-11	10,548,857	2020-02-04	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Allowed	16/116,393	2018-08-29			United States of America
Antecip Bioventures II LLC	NERIDRONIC ACID COMPLEX FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	16/152,256	2018-10-04			United States of America
Antecip Bioventures II LLC	NERIDRONIC ACID COMPLEX FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Granted	16/110,869	2018-08-23	10,350,227	2019-07-16	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS FOR SUSTAINED DELIVERY OF DEXTROMETHORPHAN	Herriot Tabuteau	Granted	16/133,553	2018-09-17	10,596,167	2020-03-24	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Abandoned	16/124,069	2018-09-06			United States of America
Assome Therapeutics, Inc.	COMPOSITIONS FOR DELIVERY OF REBOXETINE	Herriot Tabuteau	Expired	62/837,002	2019-04-22			United States of America

Antecip Bioventures II LLC	DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Granted	16/144,916	2018-09-27	10,413,560	2019-09-17	United States of America
Antecip Bioventures II LLC	NERIDRONIC ACID FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	16/152,750	2018-10-05			United States of America
Antecip Bioventures II LLC	DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Published	16/137,446	2018-09-20			United States of America
Antecip Bioventures II LLC	BUPROPION AND DEXTROMETHORPHAN FOR TREATING NICOTINE ADDICTION	Herriot Tabuteau	Published	16/130,898	2018-09-13			United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Published	201811734 34.6	2013-05-14			China
Antecip Bioventures II LLC	DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Abandoned	16/136,065	2018-09-19			United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS FOR SUSTAINED DELIVERY OF DEXTROMETHORPHAN	Herriot Tabuteau	Application	747111	2015-05-01			New Zealand

TRADEMARK

REEL: 007062 FRAME: 0345

Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Herriot Tabuteau	Published	17771287.4	2017-03-24			European Patent
Axsome Therapeutics, Inc.	DOSAGE FORMS COMPRISING ACTIVE PHARMACEUTICAL INGREDIENTS	Herriot Tabuteau	Expired	62/738,833	2018-09-28			United States of America
Axsome Therapeutics, Inc.	NERIDRONIC ACID FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Expired	62/750,772	2018-10-25			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/181,086	2018-11-05	10,265,324	2019-04-23	United States of America
Antecip Bioventures II LLC	NERIDRONIC ACID FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	16/167,371	2018-10-22			United States of America
Antecip Bioventures II LLC	COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	Herriot Tabuteau	Abandoned	2019101068 10.8	2013-05-14			China
Axsome Therapeutics, Inc.	BIPHOSPHONATES FOR TREATING CONDITIONS	Herriot Tabuteau	Expired	62/744,037	2018-10-10			United States of America
Antecip Bioventures II LLC	NERIDRONIC ACID FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	16/168,632	2018-10-23			United States of America

TRADEMARK

REEL: 007062 FRAME: 0346

Antecip Bioventures II LLC	NERIDRONIC ACID FOR TREATING REGIONAL PAIN SYNDROME	HERIOT TABUTEAU	Abandoned	16/208,413	2018-12-03			United States of America
Axsome Therapeutics, Inc.	COMPOSITIONS FOR DELIVERY OF REBOXETINE	Herriot Tabuteau	Expired	62/745,956	2018-10-15			United States of America
Axsome Therapeutics, Inc.	DOSAGE FORMS COMPRISING ACTIVE PHARMACEUTICAL INGREDIENTS	Herriot Tabuteau	Expired	62/842,394	2019-05-02			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/247,406	2019-01-14	10,322,181	2019-06-18	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Application	1020181088 8.X	2014-11-05			Singapore
Antecip Bioventures II LLC	COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Application	2018-232467	2014-08-08			Japan
Antecip Bioventures II LLC	NERIDRONIC ACID FOR TREATING REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	16/222,040	2018-12-17			United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Abandoned	16/218,383	2018-12-12			United States of America

TRADEMARK

REEL: 007062 FRAME: 0347

Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION	Herriot Tabuteau	Application	10-2018-7036244	2015-05-01			Korea, Republic of (KR)
Axsome Therapeutics, Inc.	NERIDRONIC ACID AND OTHER BISPHOSPHONATES FOR TREATING COMPLEX REGIONAL PAIN SYNDROME AND OTHER DISEASES	Herriot Tabuteau	Expired	62/776,989	2018-12-07			United States of America
Axsome Therapeutics, Inc.	NERIDRONIC ACID AND OTHER BISPHOSPHONATES FOR TREATING COMPLEX REGIONAL PAIN SYNDROME AND OTHER DISEASES	Herriot Tabuteau	Expired	62/780,153	2018-12-14			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/248,449	2019-01-15	10,363,312	2019-07-30	United States of America
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H. Dinkla Graeme Jones	Abandoned	2018-238424	2015-05-27			Japan
Antecip Bioventures II LLC	NERIDRONIC ACID FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	16/264,237	2019-01-31			United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Abandoned	18116608,0	2014-08-08			Hong Kong

TRADEMARK

REEL: 007062 FRAME: 0348



Antecip Bioventures II LLC	NERIDRONIC ACID FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Herriot Tabuteau	Abandoned	10-2019-7000076	2013-05-14			Korea, Republic of (KR)
Axsome Therapeutics, Inc.	NERIDRONIC ACID AND OTHER BIPHOSPHONATES FOR TREATING COMPLEX REGIONAL PAIN SYNDROME AND OTHER DISEASES	Herriot Tabuteau	Expired	62/801,333	2019-02-05			United States of America
Axsome Therapeutics, Inc.	COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION	Herriot Tabuteau	Expired	62/789,431	2019-01-07			United States of America
Axsome Therapeutics, Inc.	COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION	Herriot Tabuteau	Expired	62/789,446	2019-01-07			United States of America
Axsome Therapeutics, Inc.	COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION	Herriot Tabuteau	Expired	62/789,451	2019-01-07			United States of America
Axsome Therapeutics, Inc.	COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION	Herriot Tabuteau	Expired	62/789,488	2019-01-07			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Published	16/246,347	2019-01-11			United States of America
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H. Dinkla	Application	10-2019-7002069	2015-05-27			Korea, Republic of (KR)

TRADEMARK

REEL: 007062 FRAME: 0349

Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Abandoned	10-2019-7001788	2014-08-08			Korea, Republic of (KR)
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Abandoned	16/267,295	2019-02-04			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Allowed	2019203328	2016-04-11			Australia
Axsome Therapeutics, Inc.	NERIDRONIC ACID AND OTHER BISPHOSPHONATES FOR TREATING COMPLEX REGIONAL PAIN SYNDROME AND OTHER DISEASES	Herriot Tabuteau	Expired	62/802,107	2019-02-06			United States of America
Axsome Therapeutics, Inc.	MELOXICAM AND RIZATRIPTAN FOR TREATING MIGRAINE	Herriot Tabuteau	Expired	62/802,198	2019-02-06			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Expired	62/803,756	2019-02-11			United States of America
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Published	PCT/US2019/019445	2019-02-25			Patent Cooperation Treaty

TRADEMARK

REEL: 007062 FRAME: 0350

Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Published	16/290,653	2019-03-01			United States of America
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Published	PCT/US2019/052210	2019-09-20			Patent Cooperation Treaty
Axsome Therapeutics, Inc.	NERIDRONIC ACID AND OTHER BISPHOSPHONATES FOR TREATING COMPLEX REGIONAL PAIN SYNDROME AND OTHER DISEASES	Herriot Tabuteau	Abandoned	16/365,459	2019-03-26			United States of America
Axsome Therapeutics, Inc.	NERIDRONIC ACID AND OTHER BISPHOSPHONATES FOR TREATING COMPLEX REGIONAL PAIN SYNDROME AND OTHER DISEASES	Herriot Tabuteau	Abandoned	16/366,207	2019-03-27			United States of America
Antecip Bioventures II LLC	NERIDRONIC ACID AND OTHER BISPHOSPHONATES FOR TREATING COMPLEX REGIONAL PAIN SYNDROME AND OTHER DISEASES	Herriot Tabuteau	Granted	16/366,818	2019-03-27	10,413,561	2019-09-17	United States of America
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H. Dinkla Graeme Jones	Granted	2019204559	2015-05-27	2019204559	2020-07-30	Australia
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY	Herriot Tabuteau	Published	16/362,434	2019-03-22			United States of America

TRADEMARK

REEL: 007062 FRAME: 0351

	ENRICHED OR PURE BUPROPION								
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Published	16/364,005	2019-03-25			United States of America	
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Expired	62/809,480	2019-02-22			United States of America	
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Expired	62/810,233	2019-02-25			United States of America	
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Expired	62/810,880	2019-02-26			United States of America	
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Published	16/364,463	2019-03-26			United States of America	
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION	Herriot Tabuteau	Application	2019201548	2015-05-01			Australia	
Antecip Bioventures II LLC	IMPLANTABLE DEVICE FOR SUSTAINED RELEASE OF SUFENTANIL	Herriot Tabuteau	Granted	12723023.3	2012-05-10	2707032	2019-06-26	Austria	

TRADEMARK

REEL: 007062 FRAME: 0352

Antecip Bioventures II LLC	IMPLANTABLE DEVICE FOR RELEASE OF SUFENTANIL	POLYMERIC SUSTAINED	Herriot Tabuteau	Granted	12723023.3	2012-05-10	2707032	2019-06-26	Belgium
Antecip Bioventures II LLC	IMPLANTABLE DEVICE FOR RELEASE OF SUFENTANIL	POLYMERIC SUSTAINED	Herriot Tabuteau	Granted	12723023.3	2012-05-10	2707032	2019-06-26	Czechia
Antecip Bioventures II LLC	IMPLANTABLE DEVICE FOR RELEASE OF SUFENTANIL	POLYMERIC SUSTAINED	Herriot Tabuteau	Granted	12723023.3	2012-05-10	2707032	2019-06-26	Denmark
Antecip Bioventures II LLC	IMPLANTABLE DEVICE FOR RELEASE OF SUFENTANIL	POLYMERIC SUSTAINED	Herriot Tabuteau	Granted	12723023.3	2012-05-10	2707032	2019-06-26	France
Antecip Bioventures II LLC	IMPLANTABLE DEVICE FOR RELEASE OF SUFENTANIL	POLYMERIC SUSTAINED	Herriot Tabuteau	Granted	12723023.3	2012-05-10	2707032	2019-06-26	Germany (Federal Republic of)
Antecip Bioventures II LLC	IMPLANTABLE DEVICE FOR RELEASE OF SUFENTANIL	POLYMERIC SUSTAINED	Herriot Tabuteau	Granted	12723023.3	2012-05-10	2707032	2019-06-26	Ireland (Republic of)
Antecip Bioventures II LLC	IMPLANTABLE DEVICE FOR RELEASE OF SUFENTANIL	POLYMERIC SUSTAINED	Herriot Tabuteau	Granted	12723023.3	2012-05-10	2707032	2019-06-26	Italy
Antecip Bioventures II LLC	IMPLANTABLE DEVICE FOR RELEASE OF SUFENTANIL	POLYMERIC SUSTAINED	Herriot Tabuteau	Granted	12723023.3	2012-05-10	2707032	2019-06-26	Netherlands
Antecip Bioventures II LLC	IMPLANTABLE DEVICE FOR RELEASE OF SUFENTANIL	POLYMERIC SUSTAINED	Herriot Tabuteau	Granted	12723023.3	2012-05-10	2707032	2019-06-26	Norway

Antecip Bioventures II LLC	IMPLANTABLE DEVICE FOR RELEASE OF SUFENTANIL	POLYMERIC SUSTAINED	Herriot Tabureau	Granted	12723023.3	2012-05-10	2707032	2019-06-26	Poland
Antecip Bioventures II LLC	IMPLANTABLE DEVICE FOR RELEASE OF SUFENTANIL	POLYMERIC SUSTAINED	Herriot Tabureau	Granted	12723023.3	2012-05-10	2707032	2019-06-26	Portugal
Antecip Bioventures II LLC	IMPLANTABLE DEVICE FOR RELEASE OF SUFENTANIL	POLYMERIC SUSTAINED	Herriot Tabureau	Granted	12723023.3	2012-05-10	2707032	2019-06-26	Spain
Antecip Bioventures II LLC	IMPLANTABLE DEVICE FOR RELEASE OF SUFENTANIL	POLYMERIC SUSTAINED	Herriot Tabureau	Granted	12723023.3	2012-05-10	2707032	2019-06-26	Sweden
Antecip Bioventures II LLC	IMPLANTABLE DEVICE FOR RELEASE OF SUFENTANIL	POLYMERIC SUSTAINED	Herriot Tabureau	Granted	12723023.3	2012-05-10	2707032	2019-06-26	Switzerland
Antecip Bioventures II LLC	IMPLANTABLE DEVICE FOR RELEASE OF SUFENTANIL	POLYMERIC SUSTAINED	Herriot Tabureau	Granted	12723023.3	2012-05-10	2707032	2019-06-26	United Kingdom
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY		Herriot Tabureau	Published	16/359,958	2019-03-20			United States of America
Asxome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM		Herriot Tabureau	Application	2019-074133	2016-04-11			Japan
Antecip Bioventures II LLC	BUPROPION AND DEXTROMETHORPHAN FOR TREATING ADDICTION	NICOTINE	Herriot Tabureau	Granted	16/359,996	2019-03-20	10,688,066	2020-06-23	United States of America

TRADEMARK

REEL: 007062 FRAME: 0354

Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/374,081	2019-04-03	10,471,069	2019-11-12	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/372,958	2019-04-02	10,485,871	2019-11-26	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/372,977	2019-04-02	10,426,839	2019-10-01	United States of America
Axsome Therapeutics, Inc.	COMBINATION TREATMENT FOR MIGRAINE AND OTHER PAIN	Herriot Tabuteau	Granted	16/513,612	2019-07-16	10,688,102	2020-06-23	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/403,034	2019-05-03	10,456,471	2019-10-29	United States of America
Axsome Therapeutics, Inc.	COMBINATION TREATMENT FOR MIGRAINE AND OTHER PAIN	Herriot Tabuteau	Expired	62/835,613	2019-04-18			United States of America
Axsome Therapeutics, Inc.	METHODS OF MODULATING TETRABENAZINE METABOLITES PLASMA LEVELS USING BUPROPION	Herriot Tabuteau	Published	PCT/US2019/036406	2019-06-10			Patent Cooperation Treaty
Axsome Therapeutics, Inc.	COMBINATION TREATMENT FOR MIGRAINE AND OTHER PAIN	Herriot Tabuteau	Expired	62/846,311	2019-05-10			United States of America
Axsome Therapeutics, Inc.	COMPOSITIONS FOR DELIVERY OF REBOXETINE	Herriot Tabuteau	Published	PCT/US2019/037500	2019-06-17			Patent Cooperation Treaty

TRADEMARK

REEL: 007062 FRAME: 0355

Antecip Bioventures II LLC	NERIDRONIC ACID AND OTHER BISPHOSPHONATES FOR TREATING REGIONAL PAIN SYNDROME AND OTHER DISEASES	Herriot Tabuteau	Granted	16/439,121	2019-06-12	10,493,085	2019-12-03	United States of America
Antecip Bioventures II LLC	COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	Herriot Tabuteau	Published	16/452,910	2019-06-26			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Expired	62/856,962	2019-06-04			United States of America
Axsome Therapeutics, Inc.	METHODS OF MODULATING TETRABENAZINE METABOLITES PLASMA LEVELS USING BUPROPION	Herriot Tabuteau	Abandoned	PCT/US2019/036624	2019-06-11			Patent Cooperation Treaty
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/440,695	2019-06-13	10,512,692	2019-12-24	United States of America
Antecip Bioventures II LLC	"COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS".	Herriot Tabuteau	Abandoned	19125826.8	2019-06-25			Hong Kong
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Expired	62/860,705	2019-06-12			United States of America

TRADEMARK

REEL: 007062 FRAME: 0356



Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Granted	16/454,319	2019-06-27	10,512,693	2019-12-24	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Allowed	2018205790	2018-01-04			Australia
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Application	3049229	2018-01-04			Canada
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Published	201880015899.0	2018-01-04			China
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Published	18736278.5	2018-01-04			European Patent
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Application	2019-536590	2018-01-04			Japan
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Application	10-2019-7022825	2018-01-04			Korea, Republic of (KR)
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Application	755129	2018-01-04			New Zealand
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Published	PCT/US2019/040495	2019-07-03			Patent Cooperation Treaty

Antecip Bioventures II LLC	BISPHOSPHONATES FOR INCREASING THE TYPE 2 CHARACTER OF A MODIC CHANGE	Herriot Tabuteau Jaro I. Kauppinen	Abandoned	18738989.5	2018-01-12			European Patent
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING BUPROPION	Herriot Tabuteau	Published	19126324.3	2017-03-24			Hong Kong
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Application	1120190139 01-0	2018-01-04			Brazil
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Published	MX/al/2019/ 008127	2018-01-04			Mexico
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Published	NC2019/000 8364	2018-01-04			Colombia
Axsome Therapeutics, Inc.	METHODS OF MODULATING TETRABENAZINE METABOLITES PLASMA LEVELS USING BUPROPION	Herriot Tabuteau	Published	16/513,367	2019-07-16			United States of America
Axsome Therapeutics, Inc.	COMPOSITIONS FOR DELIVERY OF REBOXETINE	Herriot Tabuteau	Published	16/514,948	2019-07-17			United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Published	2019106492 07.4	2014-11-05			China

TRADEMARK

REEL: 007062 FRAME: 0358

Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Published	2019106491 98.9	2014-11-05			China
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Published	2019106491 99.3	2014-11-05			China
Antecip Bioventures II LLC	BUPROPION AND DEXTROMETHORPHAN FOR TREATING NICOTINE ADDICTION	Herriot Tabuteau	Published	16/745,105	2020-01-16			United States of America
Antecip Bioventures II LLC	OSTEOCLAST INHIBITORS FOR PAIN	Herriot Tabuteau Eric K.H. Dinkla Graeme Jones	Abandoned	1020190660 9U	2015-05-27			Singapore
Asxome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Expired	62/888,693	2019-08-19			United States of America
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION	Herriot Tabuteau	Application	3082645	2015-05-01			Canada
Asxome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Granted	16/579,305	2019-09-23	10,695,304	2020-06-30	United States of America

Axsome Therapeutics, Inc.	COMBINATION OF MELOXICAM AND RIZATRIPTAN WITH IMPROVED PHARMACOKINETICS	Herriot Tabuteau	Application	62/895,933	2019-09-04			United States of America
Axsome Therapeutics, Inc.	COMBINATION OF MELOXICAM AND RIZATRIPTAN WITH IMPROVED PHARMACOKINETICS	Herriot Tabuteau	Application	62/895,956	2019-09-04			United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Application	2019236614	2014-11-05			Australia
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/565,111	2019-09-09	10,532,101	2020-01-14	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/566,476	2019-09-10	10,537,642	2020-01-21	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/567,859	2019-09-11	10,517,950	2019-12-31	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/568,703	2019-09-12	10,729,696	2020-08-04	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/570,451	2019-09-13	10,729,697	2020-08-04	United States of America
Axsome Therapeutics, Inc.	DOSAGE FORMS COMPRISING ACTIVE PHARMACEUTICAL INGREDIENTS	Herriot Tabuteau	Published	PCT/US2019/053167	2019-09-26			Patent Cooperation Treaty

TRADEMARK

REEL: 007062 FRAME: 0360

Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/570,434	2019-09-13	10,722,583	2020-07-28	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Application	758425	2014-11-05			New Zealand
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Application	758428	2014-11-05			New Zealand
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Application	758431	2014-11-05			New Zealand
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/572,042	2019-09-16	10,729,773	2020-08-04	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/589,692	2019-10-01	10,561,664	2020-02-18	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Application	2019-185676	2015-05-01			Japan
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Application	2019-189318	2014-11-05			Japan

Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Published	16/588,399	2019-09-30			United States of America
Axsome Therapeutics, Inc.	USE OF REBOXETINE TO TREAT NARCOLEPSY	Herriot Tabuteau	Published	PCT/US2019/056134	2019-10-14			Patent Cooperation Treaty
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/653,877	2019-10-15	10,583,144	2020-03-10	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Application	2019-193246	2018-05-10			Japan
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Application	758432	2014-11-05			New Zealand
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Allowed	2018265411	2018-05-10			Australia
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Application	3063095	2018-05-10			Canada
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Published	201880030708.8	2018-05-10			China
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Published	18798779.7	2018-05-10			European Patent

TRADEMARK

REEL: 007062 FRAME: 0362

Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Application	10-2019-7035733	2018-05-10			Korea, Republic of (KR)
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Application	758664	2018-05-10			New Zealand
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/689,970	2019-11-20	10,688,185	2020-06-23	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/690,464	2019-11-21	10,695,429	2020-06-30	United States of America
Anecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Published	4202000485 9.3	2020-03-25			Hong Kong
Anecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Application	4202000556 8.9	2020-04-08			Hong Kong
Anecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Published	4202000451 6.9	2014-11-05			Hong Kong
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Published	19132917.6	2018-01-04			Hong Kong
Anecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND	Herriot Tabuteau	Allowed	16/681,317	2019-11-12			United States of America

TRADEMARK

REEL: 007062 FRAME: 0363

	RELATED PHARMACODYNAMIC EFFECTS								
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/688,491	2019-11-19	10,653,777	2020-05-19	United States of America	
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/693,052	2019-11-22	10,695,430	2020-06-30	United States of America	
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/694,440	2019-11-25	10,702,602	2020-07-07	United States of America	
Axsome Therapeutics, Inc.	USE OF REBOXETINE TO TREAT NARCOLEPSY	Herriot Tabuteau	Application	62/943,077	2019-12-03			United States of America	
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION	Herriot Tabuteau	Application	1020191187	2015-05-01			Singapore	
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Application	1020191180	2014-11-05			Singapore	
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Application	2019275593	2013-11-05			Australia	
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	Herriot Tabuteau	Application	1020191181	2014-11-05			Singapore	

TRADEMARK

REEL: 007062 FRAME: 0364



Axsome Therapeutics, Inc.	USE OF REBOXETINE TO TREAT NARCOLEPSY	Herriot Tabureau	Application	62/946,295	2019-12-10			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabureau	Application	62/948,768	2019-12-16			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabureau	Application	62/948,803	2019-12-16			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabureau	Granted	16/773,567	2020-01-27	10,702,535	2020-07-07	United States of America
Axsome Therapeutics, Inc.	COMBINATION TREATMENT FOR MIGRAINE AND OTHER PAIN	Herriot Tabureau	Application	62/955,905	2019-12-31			United States of America
Antecip Bioventures II LLC	COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION	Herriot Tabureau	Allowed	16/736,752	2020-01-07			United States of America
Axsome Therapeutics, Inc.	COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION	Herriot Tabureau	Published	PCT/US2020/012612	2020-01-07			Patent Cooperation Treaty
Axsome Therapeutics, Inc.	USE OF ESREBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS SUCH AS FIBROMYALGIA	Herriot Tabureau	Published	16/740,329	2020-01-10			United States of America
Axsome Therapeutics, Inc.	USE OF REBOXETINE TO TREAT NARCOLEPSY	Herriot Tabureau	Published	16/740,409	2020-01-11			United States of America

TRADEMARK

REEL: 007062 FRAME: 0365

Axsome Therapeutics, Inc.	USE OF ESREBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS SUCH AS FIBROMYALGIA	Herriot Tabuteau	Published	16/740,410	2020-01-11			United States of America
Axsome Therapeutics, Inc.	USE OF ESREBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS SUCH AS FIBROMYALGIA	Herriot Tabuteau	Published	16/740,411	2020-01-11			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Published	PCT/US2020/017046	2020-02-06			Patent Cooperation Treaty
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application	62/971,174	2020-02-06			United States of America
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application	62/978,626	2020-02-19			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Published	16/790,085	2020-02-13			United States of America
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Published	16/830,637	2020-03-26			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Published	16/821,330	2020-03-17			United States of America

TRADEMARK

REEL: 007062 FRAME: 0366

Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Published	16/821,462	2020-03-17			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Published	16/822,564	2020-03-18			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Published	16/822,697	2020-03-18			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Published	16/823,724	2020-03-19			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Published	16/823,807	2020-03-19			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Published	16/825,195	2020-03-20			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Published	16/825,228	2020-03-20			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Published	6202000583 5.7	2018-05-10			Hong Kong
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Published	16/806,145	2020-03-02			United States of America

TRADEMARK

Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Published	16/807,512	2020-03-03			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Published	16/826,580	2020-03-23			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Published	16/826,598	2020-03-23			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Published	16/828,237	2020-03-24			United States of America
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION	Herriot Tabuteau	Published	2020102023 97.8	2015-05-01			China
Antecip Bioventures II LLC	BUPROPION AND DEXTROMETHORPHAN FOR TREATING NICOTINE ADDICTION	Herriot Tabuteau	Allowed	16/817,119	2020-03-12			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Published	16/852,939	2020-04-20			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Granted	16/853,062	2020-04-20	10,780,064	2020-09-22	United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR	Herriot Tabuteau	Application	MX/a/2020/ 004075	2014-11-05			Mexico

TRADEMARK

REEL: 007062 FRAME: 0368

	RELATED COMPOUNDS AND DEXTROMETHORPHAN								
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Granted	16/838,829	2020-04-02	10,772,850	2020-09-15	United States of America	
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Published	16/832,153	2020-03-27			United States of America	
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application	62/992,060	2020-03-19			United States of America	
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/834,077	2020-03-30	10,729,774	2020-08-04	United States of America	
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/835,848	2020-03-31	10,758,617	2020-09-01	United States of America	
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/837,769	2020-04-01	10,780,165	2020-09-22	United States of America	
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Allowed	16/841,436	2020-04-06			United States of America	
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Allowed	16/842,063	2020-04-07			United States of America	

TRADEMARK

REEL: 007062 FRAME: 0369

Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/843,490	2020-04-08	10,758,618	2020-09-01	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Granted	16/844,634	2020-04-09	10,780,166	2020-09-22	United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Published	16/854,320	2020-04-21			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Application	63/002,132	2020-03-30			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Application	63/006,023	2020-04-06			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Published	16/857,435	2020-04-24			United States of America
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS FOR SUSTAINED DELIVERY OF DEXTROMETHORPHAN	Herriot Tabuteau	Application	764072	2015-05-01			New Zealand
Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS FOR SUSTAINED DELIVERY OF DEXTROMETHORPHAN	Herriot Tabuteau	Application	764077	2015-05-01			New Zealand

TRADEMARK

REEL: 007062 FRAME: 0370

Antecip Bioventures II LLC	COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS FOR SUSTAINED DELIVERY OF DEXTROMETHORPHAN	Herriot Tabuteau	Application	764088	2015-05-01			New Zealand
Antecip Bioventures II LLC	BUPROPION AND DEXTROMETHORPHAN FOR TREATING AGITATION IN ALZHEIMER'S DISEASE	Herriot Tabuteau	Application	63/016,178	2020-04-27			United States of America
Antecip Bioventures II LLC	BUPROPION AND DEXTROMETHORPHAN FOR TREATING AGITATION IN ALZHEIMER'S DISEASE	Herriot Tabuteau	Application	63/016,208	2020-04-27			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Allowed	16/867,929	2020-05-06			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Application	6202000958 2.1	2020-06-18			Hong Kong
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application	16/907,691	2020-06-22			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Application	16/927,623	2020-07-13			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Application	16/885,975	2020-05-28			United States of America

TRADEMARK

REEL: 007062 FRAME: 0371

Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Application	16/894,713	2020-06-05			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Application	6202000959 2.0	2020-06-18			Hong Kong
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Application	63/032,517	2020-05-29			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Application	63/032,567	2020-05-30			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Application	16/921,006	2020-07-06			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Application	2020205306	2016-04-11			Australia
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application	16/923,420	2020-07-08			United States of America
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application	16/924,510	2020-07-09			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Application	16/926,458	2020-07-10			United States of America

TRADEMARK

REEL: 007062 FRAME: 0372



Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application	PCT/US2020/046755	2020-08-18			Patent Cooperation Treaty
Axsome Therapeutics, Inc.	METHODS OF MODULATING TETRABENAZINE METABOLITES PLASMA LEVELS USING BUPROPION	Herriot Tabuteau	Application	16/931,907	2020-07-17			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Application	16/997,740	2020-08-19			United States of America
Axsome Therapeutics, Inc.	PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	Herriot Tabuteau	Application	16/998,622	2020-08-20			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Application	16/983,873	2020-08-03			United States of America
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Albania
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Austria
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Belgium

TRADEMARK

REEL: 007062 FRAME: 0373

Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Bulgaria
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Croatia
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Cyprus (Republic of)
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Czechia
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Denmark
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Estonia
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Finland
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	France

	ERYTHROHYDROXYBUPROPIO N								
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Germany (Federal Republic of)	
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Greece	
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Hungary	
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Iceland	
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Ireland (Republic of)	
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Italy	
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Latvia	

TRADEMARK

REEL: 007062 FRAME: 0375

Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Liechtenstei n
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Lithuania
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Luxembourg
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Malta
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Monaco
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Netherlands
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	North Macedonia
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Norway

	ERYTHROHYDROXYBUPROPIO N								
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Poland	
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Portugal	
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Romania	
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	San Marino	
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Serbia	
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Slovak Republic	
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Slovenia	

TRADEMARK

REEL: 007062 FRAME: 0377

Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Spain
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Sweden
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Switzerland
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	Turkey
Antecip Bioventures II LLC	METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPIO N	Herriot Tabuteau	Granted	15861189.7	2015-05-01	3220909	2020-09-02	United Kingdom
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Application	17/002,017	2020-08-25			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Application	17/003,777	2020-08-26			United States of America
Antecip Bioventures II LLC	TREATMENTS COMPRISING A COMBINATION OF DEXTROMETHORPHAN AND BUPROPION	Herriot Tabuteau	Application	20193845.3	2015-05-01			European Patent

TRADEMARK

REEL: 007062 FRAME: 0378

Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONMERICALLY ENRICHED BUPROPION	Herriot Tabuteau	Application	2019223187	2019-02-25			Australia
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONMERICALLY ENRICHED PURE BUPROPION	Herriot Tabuteau	Application		2019-02-25			Belize
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application	BR 1120200171 79-4	2019-02-25			Brazil
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application		2019-02-25			Canada
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application	202002166	2019-02-25			Chile
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application	2020002720 5	2019-02-25			El Salvador
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application	A2020-000127	2019-02-25			Guatemala
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application	2020-000582	2019-02-25			Honduras

TRADEMARK

REEL: 007062 FRAME: 0379

	ENRICHED OR PURE BUPROPION								
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application	276871	2019-02-25				Israel
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application		2019-02-25				Japan
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application	PI20200043 15	2019-02-25				Malaysia
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application	MX/a/2020/ 008704	2019-02-25				Mexico
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application	767378	2019-02-25				New Zealand
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application		2019-02-25				Nicaragua
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIONMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application	93176-01	2019-02-25				Panama

TRADEMARK

REEL: 007062 FRAME: 0380



Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application			2019-02-25			Peru
Axsome Therapeutics, Inc.	DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	Herriot Tabuteau	Application	11202008056S		2019-02-25			Singapore
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Application	17/020,393		2020-9-14			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Application	17/022,629		2020-9-16			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Application	17/022,781		2020-9-16			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Application	17/030,129		2020-9-23			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Application	17/024,145		2020-9-17			United States of America
Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Application	17/025,849		2020-9-18			United States of America

TRADEMARK

REEL: 007062 FRAME: 0381

Antecip Bioventures II LLC	BUPROPION AS A MODULATOR OF DRUG ACTIVITY	Herriot Tabuteau	Application	17/027,608	2020-9-21				United States of America
----------------------------------	--	---------------------	-------------	------------	-----------	--	--	--	-----------------------------------

**TRADEMARK**

**REEL: 007062 FRAME: 0382**

EXHIBIT C  
Trademarks

Mark Name	Status	Application Number	Filed Date	Registration Number	Registration Date	Country
AXSOME	Registered	1303688	2016-03-01	1786133	2016-03-01	Australia
AXSOME	Application	1,769,944	2016-02-29			Canada
AXSOME	Registered	1303688	2016-03-01	1303688	2016-03-01	China
AXSOME	Registered	1303688	2016-03-01	1303688	2016-03-01	European Union
AXSOME	Registered	IRDI-3379940	2016-03-01	1303688	2016-03-01	India
AXSOME	Registered	1303688	2016-03-01	1303688	2016-03-01	Japan
AXSOME	Registered	1303688	2016-03-01	1303688	2016-03-01	Korea, Republic of (KR)
AXSOME	Registered	1303688	2016-03-01	1303688	2016-03-01	New Zealand
AXSOME	Registered	86/744,028	2015-09-01	5,530,595	2018-07-31	United States of America
AXSOME	Registered	1303688	2016-03-01	1303688	2016-03-01	International
AXSOME THERAPEUTICS	Registered	1303581	2016-03-01	1784921	2016-03-01	Australia
AXSOME THERAPEUTICS	Application	1,770,087	2016-03-01			Canada
AXSOME THERAPEUTICS	Registered	1303581	2016-03-01	1303581	2016-03-01	China
AXSOME THERAPEUTICS	Registered	1303581	2016-03-01	1303581	2016-03-01	European Union
AXSOME THERAPEUTICS	Registered	IRDI-3378436	2016-03-01	1303581	2016-03-01	India
AXSOME THERAPEUTICS	Registered	1303581	2016-03-01	1303581	2016-03-01	Japan
AXSOME THERAPEUTICS	Registered	1303581	2016-03-01	1303581	2016-03-01	Korea, Republic of (KR)

Mark Name	Status	Application Number	Filed Date	Registration Number	Registration Date	Country
AXSOME THERAPEUTICS	Registered	1303581	2016-03-01	1303581	2016-03-01	New Zealand
AXSOME THERAPEUTICS	Registered	86/744,113	2015-09-01	5,519,927	2018-07-17	United States of America
AXSOME THERAPEUTICS	Registered	1303581	2016-03-01	1303581	2016-03-01	International
SENVVOYA	Application	88/934,922	2020-05-27			United States of America
TREVASA	Application	88/934,950	2020-05-27			United States of America
ALLARISA	Application	88/927,370	2020-05-21			United States of America
SIMTRUYA	Application	88/937,142	2020-05-28			United States of America

TRADEMARK

EXHIBIT D  
Mask Works

None.

US-DOCS\117785767.4